Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy

Abstract Background Immunotherapy in colorectal cancer (CRC) regulates specific immune checkpoints and, when used in combination with chemotherapy, can improve patient prognosis. One specific immune checkpoint is the recruitment of circulating monocytes that differentiate into tumor-associated macro...

Full description

Bibliographic Details
Main Authors: Shelby N. Bess, Gage J. Greening, Narasimhan Rajaram, Timothy J. Muldoon
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Immunology
Subjects:
Online Access:https://doi.org/10.1186/s12865-022-00493-5
_version_ 1828400006848053248
author Shelby N. Bess
Gage J. Greening
Narasimhan Rajaram
Timothy J. Muldoon
author_facet Shelby N. Bess
Gage J. Greening
Narasimhan Rajaram
Timothy J. Muldoon
author_sort Shelby N. Bess
collection DOAJ
description Abstract Background Immunotherapy in colorectal cancer (CRC) regulates specific immune checkpoints and, when used in combination with chemotherapy, can improve patient prognosis. One specific immune checkpoint is the recruitment of circulating monocytes that differentiate into tumor-associated macrophages (TAMs) and promote tumor angiogenesis. Changes in vascularization can be non-invasively assessed via diffuse reflectance spectroscopy using hemoglobin concentrations and oxygenation in a localized tumor volume. In this study, we examine whether blockade of monocyte recruitment via CCL2 (macrophage chemoattractant protein-1) leads to enhanced sensitivity of 5-fluorouracil (5-FU) in a CT26-Balb/c mouse model of CRC. It was hypothesized that the blockade of TAMs will alter tumor perfusion, increasing chemotherapy response. A subcutaneous tumor model using Balb/c mice injected with CT26 colon carcinoma cells received either a saline or isotype control, anti-CCL2, 5-FU, or a combination of anti-CCL2 and 5-FU. Results Findings show that 12 days post-treatment, monocyte recruitment was significantly reduced by approximately 61% in the combination group. This shows that the addition of anti-CCL2 to 5-FU slowed the fold-change (change from the original measurement to the final measurement) in tumor volume from Day 0 to Day 12 (~ 5 fold). Modest improvements in oxygen saturation (~ 30%) were observed in the combination group. Conclusion The findings in this work suggest that the blockade of CCL2 is sufficient in the reduction of TAMs that are recruited into the tumor microenvironment and has the ability to modestly alter tumor perfusion during early-tumor response to treatment even though the overall benefit is relatively modest.
first_indexed 2024-12-10T09:24:57Z
format Article
id doaj.art-b4795f8985c64b92b7e0c5d09c1762e7
institution Directory Open Access Journal
issn 1471-2172
language English
last_indexed 2024-12-10T09:24:57Z
publishDate 2022-04-01
publisher BMC
record_format Article
series BMC Immunology
spelling doaj.art-b4795f8985c64b92b7e0c5d09c1762e72022-12-22T01:54:34ZengBMCBMC Immunology1471-21722022-04-0123111410.1186/s12865-022-00493-5Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopyShelby N. Bess0Gage J. Greening1Narasimhan Rajaram2Timothy J. Muldoon3Department of Biomedical Engineering, University of Arkansas, 1 University of ArkansasDepartment of Biomedical Engineering, University of Arkansas, 1 University of ArkansasDepartment of Biomedical Engineering, University of Arkansas, 1 University of ArkansasDepartment of Biomedical Engineering, University of Arkansas, 1 University of ArkansasAbstract Background Immunotherapy in colorectal cancer (CRC) regulates specific immune checkpoints and, when used in combination with chemotherapy, can improve patient prognosis. One specific immune checkpoint is the recruitment of circulating monocytes that differentiate into tumor-associated macrophages (TAMs) and promote tumor angiogenesis. Changes in vascularization can be non-invasively assessed via diffuse reflectance spectroscopy using hemoglobin concentrations and oxygenation in a localized tumor volume. In this study, we examine whether blockade of monocyte recruitment via CCL2 (macrophage chemoattractant protein-1) leads to enhanced sensitivity of 5-fluorouracil (5-FU) in a CT26-Balb/c mouse model of CRC. It was hypothesized that the blockade of TAMs will alter tumor perfusion, increasing chemotherapy response. A subcutaneous tumor model using Balb/c mice injected with CT26 colon carcinoma cells received either a saline or isotype control, anti-CCL2, 5-FU, or a combination of anti-CCL2 and 5-FU. Results Findings show that 12 days post-treatment, monocyte recruitment was significantly reduced by approximately 61% in the combination group. This shows that the addition of anti-CCL2 to 5-FU slowed the fold-change (change from the original measurement to the final measurement) in tumor volume from Day 0 to Day 12 (~ 5 fold). Modest improvements in oxygen saturation (~ 30%) were observed in the combination group. Conclusion The findings in this work suggest that the blockade of CCL2 is sufficient in the reduction of TAMs that are recruited into the tumor microenvironment and has the ability to modestly alter tumor perfusion during early-tumor response to treatment even though the overall benefit is relatively modest.https://doi.org/10.1186/s12865-022-00493-5Colorectal cancerTumor-associated macrophagesDiffuse reflectance spectroscopyImmunomodulation
spellingShingle Shelby N. Bess
Gage J. Greening
Narasimhan Rajaram
Timothy J. Muldoon
Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
BMC Immunology
Colorectal cancer
Tumor-associated macrophages
Diffuse reflectance spectroscopy
Immunomodulation
title Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
title_full Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
title_fullStr Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
title_full_unstemmed Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
title_short Macrophage-targeted anti-CCL2 immunotherapy enhances tumor sensitivity to 5-fluorouracil in a Balb/c-CT26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
title_sort macrophage targeted anti ccl2 immunotherapy enhances tumor sensitivity to 5 fluorouracil in a balb c ct26 murine colon carcinoma model measured using diffuse reflectance spectroscopy
topic Colorectal cancer
Tumor-associated macrophages
Diffuse reflectance spectroscopy
Immunomodulation
url https://doi.org/10.1186/s12865-022-00493-5
work_keys_str_mv AT shelbynbess macrophagetargetedanticcl2immunotherapyenhancestumorsensitivityto5fluorouracilinabalbcct26murinecoloncarcinomamodelmeasuredusingdiffusereflectancespectroscopy
AT gagejgreening macrophagetargetedanticcl2immunotherapyenhancestumorsensitivityto5fluorouracilinabalbcct26murinecoloncarcinomamodelmeasuredusingdiffusereflectancespectroscopy
AT narasimhanrajaram macrophagetargetedanticcl2immunotherapyenhancestumorsensitivityto5fluorouracilinabalbcct26murinecoloncarcinomamodelmeasuredusingdiffusereflectancespectroscopy
AT timothyjmuldoon macrophagetargetedanticcl2immunotherapyenhancestumorsensitivityto5fluorouracilinabalbcct26murinecoloncarcinomamodelmeasuredusingdiffusereflectancespectroscopy